BCRX

Over the past six months (April-October 2026), BioCryst Pharmaceuticals' stock has been influenced by several events. The company held its First Quarter 2026 Earnings Call on May 6 and participated in the Jefferies Global Healthcare Conference on June 3. On June 29, BioCryst announced a strategic shift to wind down internal discovery programs and close its Birmingham research facility to focus on external innovation. David W. Jenkins was appointed Chief Scientific Officer on July 15. Strong Second Quarter 2026 financial results were reported on August 5, with total net revenue of $218.3 million and ORLADEYO net revenue of $158.2 million, leading to an increased full-year 2026 total revenue guidance. The company began shipping ORLADEYO oral pellets to pediatric patients on August 3, and ORLADEYO was approved for pediatric HAE patients in Japan on August 25. BioCryst presented at an investor conference on September 1 and participated in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15. On October 5, a Scientific Advisory Board was formed to drive rare disease pipeline innovation. The stock price increased by 12.58% over the last 12 months but decreased by 12.97% in the past month, reaching $8.29 as of October 8, 2026.